Abstract
Metal ions, particularly copper, zinc and iron, are implicated in several amyloidogenic neurodegenerative disorders. In the brain, as elsewhere in the body, metal ion excess or deficiency can potentially inhibit protein function, interfere with correct protein folding or, in the case of iron or copper, promote oxidative stress. The involvement of metal ions in neurodegenerative disorders has made them an emerging target for therapeutic interventions. One approach has been to chelate and sequester the ions and thus limit their potential to interfere with protein folding or render them unable to undergo redox processes. Newer approaches suggest that redistributing metal ions has therapeutic benefits, and recent studies indicate that alleviating cellular copper deficiency may be a plausible way to limit neurodegeneration. In this review we discuss the role of metals in amyloidogenic, neurodegenerative disorders and highlight some mechanisms and compounds used in various therapeutic approaches.
Keywords: Alzheimer's, chelator, copper, iron, neurodegeneration, Parkinson's, prion, redox, Creutzfeldt-Jakob disease, oxidative stress, neurodegenerative disorders, synucleinopathies, synuclein, zinc
Current Topics in Medicinal Chemistry
Title: Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease
Volume: 11 Issue: 5
Author(s): Alison C. Badrick and Christopher E. Jones
Affiliation:
Keywords: Alzheimer's, chelator, copper, iron, neurodegeneration, Parkinson's, prion, redox, Creutzfeldt-Jakob disease, oxidative stress, neurodegenerative disorders, synucleinopathies, synuclein, zinc
Abstract: Metal ions, particularly copper, zinc and iron, are implicated in several amyloidogenic neurodegenerative disorders. In the brain, as elsewhere in the body, metal ion excess or deficiency can potentially inhibit protein function, interfere with correct protein folding or, in the case of iron or copper, promote oxidative stress. The involvement of metal ions in neurodegenerative disorders has made them an emerging target for therapeutic interventions. One approach has been to chelate and sequester the ions and thus limit their potential to interfere with protein folding or render them unable to undergo redox processes. Newer approaches suggest that redistributing metal ions has therapeutic benefits, and recent studies indicate that alleviating cellular copper deficiency may be a plausible way to limit neurodegeneration. In this review we discuss the role of metals in amyloidogenic, neurodegenerative disorders and highlight some mechanisms and compounds used in various therapeutic approaches.
Export Options
About this article
Cite this article as:
C. Badrick Alison and E. Jones Christopher, Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease, Current Topics in Medicinal Chemistry 2011; 11 (5) . https://dx.doi.org/10.2174/156802611794785181
DOI https://dx.doi.org/10.2174/156802611794785181 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic: Central and Peripheral Metabolic Changes in Neurodegenerative Diseases (Guest Editor: Ana Cristina Rego)]
Current Drug Targets Local Melatonin Regulates Inflammation Resolution: A Common Factor in Neurodegenerative, Psychiatric and Systemic Inflammatory Disorders
CNS & Neurological Disorders - Drug Targets Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets GPCR Binding Technologies: An Overview
Current Topics in Medicinal Chemistry Huntingtons Disease: The Value of Transcranial Meganetic Stimulation
Current Medicinal Chemistry Green Synthesis of Phosphoryl-2-Oxo-2H-Pyran via Three Component Reaction of Trialkyl Phosphites
Combinatorial Chemistry & High Throughput Screening Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function
Current Neuropharmacology Cyclin-Dependent Kinase 5 (Cdk5): A Potential Therapeutic Target for the Treatment of Neurodegenerative Diseases and Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Ethnobotanical Treatment Strategies Against Alzheimers Disease
Current Alzheimer Research Role of Oxidative Stress and Metal Toxicity in the Progression of Alzheimer’s Disease
Current Neuropharmacology Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Recent Progress in Gene Therapy for Parkinson’s Disease
Current Molecular Medicine Myopathic Involvement and Mitochondrial Pathology in Kennedy Disease and in Other Motor Neuron Diseases
Current Molecular Medicine Pathogenic Role of Serine Protease HtrA2/Omi in Neurodegenerative Diseases
Current Protein & Peptide Science Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer’s Disease
Current Alzheimer Research CHIP Knockdown Reduced Heat Shock Response and Protein Quality Control Capacity in Lens Epithelial Cells
Current Molecular Medicine Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Ameliorative Effect of Trans-Sinapic Acid and its Protective Role in Cerebral Hypoxia in Aluminium Chloride Induced Dementia of Alzheimer's Type
CNS & Neurological Disorders - Drug Targets A Mini Review on the Chemistry and Neuroprotective Effects of Silymarin
Current Drug Targets Commentary: Research Highlights ATF4: The Perpetrator in Axonal-Mediated Neurodegeneration in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets